Population Pharmacokinetic–Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis

BACKGROUND: Sarilumab is a human monoclonal antibody blocking the interleukin-6 receptor alpha (IL-6Rɑ) approved for the treatment of moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to other disease-modifying antirheumatic drugs. OBJECTIVE: The ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Lei, Xu, Christine, Paccaly, Anne, Kanamaluru, Vanaja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658085/
https://www.ncbi.nlm.nih.gov/pubmed/32451909
http://dx.doi.org/10.1007/s40262-020-00899-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658085/
https://www.ncbi.nlm.nih.gov/pubmed/32451909
http://dx.doi.org/10.1007/s40262-020-00899-7

Ejemplares similares